---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-002145"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2023-02-03T23:59:59+00:00"
generated_at: "2026-06-20T01:02:04.139227+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience Q1 FY2023 revenue $54.2M (+29% YoY), net loss narrows

## Summary
- Revenue $54.2M, up 29% YoY; orders $64.7M, up 30% YoY.
- Net loss of $41.8M ($0.74/share) improved from $45.6M ($0.91/share) YoY.
- Cash and investments $438.7M; first products shipped from Wilsonville Factory of the Future.
- Customer count 2,060 (up from ~1,800); gene shipments ~134,000 (vs ~125,000).
- Launched NGS panels for rare disease; Astellas collaboration; biopharma partners at 278 with 95 active programs.

## SEC filing metadata
- accession: 0001628280-23-002145
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2023-02-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000162828023002145/0001628280-23-002145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000162828023002145/twist-20230203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-002145
- JSON: https://secwatch.observer/filing/0001628280-23-002145.json
- Plain text: https://secwatch.observer/filing/0001628280-23-002145.txt

## Key facts
- Earnings Releases
  Twist Bioscience Corp reported first quarter of fiscal 2023 ended December 31, 2022 results: revenue $54.2 million, net income $41.8 million, EPS $0.74 per share.
  - Period: first quarter of fiscal 2023 ended December 31, 2022
  - Revenue: $54.2 million
  - Net income: $41.8 million
  - EPS: $0.74 per share
  - Result: reported results
  source text: • Revenue: Total revenues for the first quarter of fiscal 2023 were $54.2 million compared to $42.0 million for the same period of fiscal 2022 . • Cost of Revenues: Cost of revenues for the first quarter of fiscal 2023 was $29.4 million compared to $27.1 million for the same period of fiscal 2022 . • Research and Development Expenses: Research and development expenses for the first quarter of fiscal 2023 were $31.2 million compared to $22.6 million for the same period of fiscal 2022 . • Selling, General and Administrative Expenses: Selling, general and administrative expenses for the first quarter of fiscal 2023 were $42.3 million compared to $51.1 million for the same period of fiscal 2022 . • Net Loss: Net loss attributable to common stockholders for the first quarter of fiscal 2023 was $41.8 million, or $0.74 per share, compared to $45.6 million, or $0.91 per share, for the same period of fiscal 2022 .
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000162828023002145/0001628280-23-002145-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.